New combo therapy offers hope for older leukemia patients
NCT ID NCT03480438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment approach for adults over 55 with a specific type of leukemia (B-precursor ALL). The goal was to see if using a targeted drug called blinatumomab along with a reduced dose of chemotherapy could help patients achieve remission with fewer side effects. The trial enrolled 52 participants and measured how many achieved complete remission after the first treatment cycle.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-PRECURSOR ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité - Campus Benjamin Franklin
Berlin, Germany
-
Evangelisches Krankenhaus Essen-Werden
Essen, Germany
-
Evangelisches Krankenhaus Hamm
Hamm, Germany
-
Gemeinschaftsklinikum Mittelrhein
Koblenz, Germany
-
Helios Klinikum Wuppertal
Wuppertal, Germany
-
Klinikum Bremen Mitte
Bremen, Germany
-
Klinikum Großhadern
München, Germany
-
Klinikum Oldenburg
Oldenburg, Germany
-
Klinikum rechts der Isar der TU München
München, Germany
-
Städtisches Klinikum Braunschweig
Braunschweig, Germany
-
Städtisches Klinikum Karlsruhe
Karlsruhe, Germany
-
Uniklinik Hamburg Eppendorf
Hamburg, Germany
-
Uniklinik RWTH Aachen
Aachen, Germany
-
Uniklinik Würzburg
Würzburg, Germany
-
University Hospital of Frankfurt (Main)
Frankfurt am Main, Hesse, 60590, Germany
-
Universitätsklinik Tübingen
Tübingen, Germany
-
Universitätsklinikum Halle
Halle, Germany
-
Universitätsklinikum Leipzig
Leipzig, Germany
-
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
-
Universitätsklinikum Ulm
Ulm, Germany
-
Vivantes Klinikum Neukölln
Berlin, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.